Related Experiment Video
Updated: Sep 29, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Mechanical thrombectomy in COVID-19-associated ischaemic stroke: patient characteristics and outcomes in a
Katarzyna Sawczyńska1,2, Paweł Wrona3,4, Tomasz Kęsek4
1Department of Neurology, Jagiellonian University Medical College, Krakow, Poland. katarzyna.sawczynska@gmail.com.
Insights
COVID-19 did not significantly impact outcomes for acute ischemic stroke (AIS) patients undergoing mechanical thrombectomy (MT). However, COVID-19 positive patients experienced longer hospital stays and delays in groin puncture, highlighting potential pandemic-related treatment challenges.
Area of Science:
- Neurology
- Infectious Diseases
- Cardiology
Background:
- COVID-19 is recognized as a risk factor for acute ischemic stroke (AIS).
- The pandemic saw a global decrease in mechanical thrombectomy (MT) procedures.
- Existing research on MT outcomes in COVID-19 associated AIS presents conflicting findings.
Purpose of the Study:
- To evaluate the clinical characteristics and outcomes of AIS patients treated with MT.
- To compare outcomes between patients with and without SARS-CoV-2 infection during the pandemic.
- To identify potential disparities in stroke care due to COVID-19.
Main Methods:
- Retrospective analysis of AIS patients treated with MT at a Comprehensive Stroke Centre.
- Comparison of clinical profiles, stroke size, and short-term outcomes between COVID-19 positive and negative groups.
- Utilized perfusion CT with RAPID software for stroke size assessment.
Main Results:
- No statistically significant differences in clinical profiles, stroke size, or patient outcomes (NIHSS, mRS, mortality) were observed between COVID-19 positive and negative groups.
- A significant increase in time from hospital arrival to groin puncture was noted in COVID-19 positive patients.
- COVID-19 positive patients had a significantly longer hospitalisation duration.
Conclusions:
- Concomitant SARS-CoV-2 infection did not negatively affect the outcomes of AIS patients treated with MT.
- Further validation in larger, multicentre studies is recommended to confirm these findings.
- The study highlights potential delays in MT procedures for COVID-19 patients during the pandemic.
Introduction:
The aim of this study was to assess the clinical profiles and outcomes of patients with confirmed COVID-19 infection and acute ischaemic stroke (AIS) treated with mechanical thrombectomy (MT) at the Comprehensive Stroke Centre (CSC) of the University Hospital in Krakow.
Clinical Rationale For The Study:
COVID-19 is a risk factor for AIS and worsens prognosis in patients with large artery occlusions. During the pandemic, the global number of MT has dropped. At the same time, studies assessing outcomes of this treatment in COVID-19-associated AIS have produced divergent results.
Material And Methods:
In this single-centre study, we retrospectively analysed and compared the clinical profiles (age, sex, presence of cardiovascular risk factors, neurological deficit at admission), stroke size (measured using postprocessing analysis of perfusion CT with RAPID software), time from stroke onset to arrival at the CSC, time from arrival at the CSC to groin puncture, treatment with intravenous thrombolysis, length of hospitalisation, laboratory test results, and short-term outcomes (measured with Thrombolysis in Cerebral Infarction scale, modified Rankin Scale and National Health Institute Stroke Scale) in patients with AIS treated with MT during the pandemic. A comparison between patients with and without concomitant SARS-CoV2 infection was then performed.
Results:
There were no statistically significant differences between 15 COVID (+) and 167 COVID (-) AIS patients treated with AIS with respect to clinical profiles (p > 0.05), stroke size (p > 0.05) or outcomes (NIHSS at discharge, 8.1 (SD = 7.1) vs. 8.8 (SD = 9.6), p = 0.778, mRS at discharge 2.9 (SD = 2) vs. 3.1 (SD = 2.1), p = 0.817, death rate 6.7% vs. 12.6%, p = 0.699). There was a significant difference between patients with and without COVID-19 concerning time from arrival at the CSC to groin puncture [104.27 (SD = 51.47) vs. 97.63 (SD = 156.94) min., p = 0.044] and the length of hospitalisation [23.7 (SD = 11.9) vs. 10.5 (SD = 6.9) days, p < 0.001].
Conclusion:
In AIS patients treated with MT, concomitant SARS-CoV2 infection did not affect the outcome. Our observations need to be confirmed in larger, and preferably multicentre, studies.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies

